New Phase 3 Study Shows that Gazyva® (obinutuzumab) Significantly Reduces Lupus Disease Activity in SLE
A new Phase 3 study published in the New England Journal of Medicine found that Gazyva® (obinutuzumab) significantly reduced disease...
Search Results
You searched for: lupus nephritis
Results found: 1152
An IDEAL Initiative in Lupus Research: Q&A With Dr. Stacie Bell, Lupus Therapeutics, and Dr. Teodora Staeva, Lupus Research Alliance
Could diet and gut health impact the lived experience of lupus? This intriguing question lies at the heart of...
Lupus Landmark Study
The Lupus Landmark Study (LLS) is a groundbreaking initiative designed to accelerate the development of personalized treatments for people...
PLK1, a potential novel therapeutic target for lupus
IDO2, a novel therapeutic target for the treatment of lupus
The Rheumatology Research Foundation and the Lupus Research Alliance Join Forces to Offer Funding to Address Lupus
Amid ongoing fluctuations in federal research funding, a declining physician workforce, and increasing patient needs, the Rheumatology Research Foundation...
The Lupus Research Alliance and Rheumatology Research Foundation Commit $1.9M to Empower Early-Career Scientists
Leading rheumatology research organizations unite to support the research workforce and fuel lupus breakthroughs. Today, the Lupus Research Alliance...
New Findings from Lupus Research Alliance-Funded Researcher Links Common Gut Bacteria to Lupus Flares
LRA-funded researcher Gregg Silverman, MD, NYU Grossman School of Medicine, is the lead author on a new study published...
Molecular Profiles and Genetic Origins of Ancestral Phenotypic Diversity
This grant was awarded to an international team of scientists who will identifying ancestry-specific lupus molecular profiles that could...
Saphnelo™ Approved as Self-Administered Autoinjector
The U.S. Food and Drug Administration just granted approval for a self-administered, once-weekly autoinjector of Saphenlo (anifrolumab), for the treatment of adult patients...
Late-Breaking Data at EULAR Shows Investigational Drug Nipocalimab Significantly Reduces Disease Activity in Lupus
The Lupus Research Alliance is encouraged by positive late-breaking Phase 2 data with nipocalimab, an investigational drug in development by Johnson & Johnson showing significantly reduced disease activity in...
New Phase 2 Data Showed that Litifilimab Significantly Reduced Disease Activity in Cutaneous Lupus Erythematosus
The Lupus Research Alliance welcomes new results from the Phase 2 part of the AMETHYST Phase 2/3 study, showing that the...